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Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability,
and decreased quality of life (QOL). Inhibition of Janus kinase (JAK) signaling ameliorates articular inflammation and
joint destruction in animal models of RA, but its effects on behaviors indicating well-being are poorly understood.
In this study, we evaluated the effect of JAK inhibition on spontaneous locomotor activity in rats with adjuvant-
induced arthritis, a rodent model of RA.
Methods: Arthritis was induced in male Lewis rats by a single subcutaneous injection of Freund’s complete
adjuvant. The novel JAK inhibitor JTE-052 was orally administered for 7 days after the onset of arthritis.
Results: Induction of arthritis suppressed the spontaneous locomotor activity of the rats. Administration of JTE-052
completely improved the spontaneous locomotor activity, with partial reductions in articular inflammation and joint
destruction. Hyperalgesia and motor functions were also improved, but the efficacy was not complete. However,
serum interleukin (IL)-6 levels were completely decreased at 4 h after administration of the first dose of JTE-052.
Conclusions: This study demonstrated that JAK inhibition improved the spontaneous locomotor activity of rats
with adjuvant-induced arthritis, in association with amelioration of pain and physical dysfunction as a consequence
of suppression of joint inflammation. Moreover, although further studies are needed, there was possible participation of
IL-6 downregulation in the improvement of locomotor activity by JAK inhibition.
Keywords: JAK inhibition, JTE-052, Rheumatoid arthritis, Spontaneous locomotor activity, Pain-related behavior, Motor
function, Quality of life, Adjuvant-induced arthritis
Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease of the distal joints characterized by hypertrophy
and hyperplasia of the synovial epithelium, destruction
of cartilage and bone, and joint infiltration by inflamma-
tory cells such as T cells, monocytes/macrophages, and
neutrophils. The quality of life (QOL) of RA patients is
affected by pain and joint dysfunction. Cytokines such as
interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-15,
and granulocyte/macrophage-colony stimulating factor
have been implicated in the pathogenesis of RA [1].
Janus kinase (JAK) is a non-receptor type tyrosine kin-
ase family composed of four enzymes (JAK1, JAK2,
JAK3, and Tyk2) that transduce signaling from multiple
type I and type II cytokine receptors and mediate vari-
ous inflammatory responses [2]. Several small-molecule
JAK inhibitors are currently in clinical development for
the treatment of transplant rejection, hematopoietic dis-
orders, and autoimmune and inflammatory diseases,
including RA [3]. Among them, tofacitinib, which was
launched in 2012 for patients with severe or moderate
RA, demonstrated significant efficacy for RA in multiple
Phase II and Phase III trials, attenuated RA symptoms
and structural damage, and improved patient QOL and
physical function indexes (HAQ-DI and SF-36) [4, 5].
Preclinical studies showed that JAK inhibitors were
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efficacious in animal models of RA, such as adjuvant-
induced arthritis (AIA) and collagen-induced arthritis
(CIA), and improved articular inflammation and joint
destruction [6–8]. However, the effects of JAK inhibitors
on behaviors indicating well-being in animal models of
RA are poorly understood.
Millecamps et al. [9] advocated the testing of spontan-
eous behaviors in rats with chronic inflammation as a
new mode for global assessment of well-being in preclin-
ical studies. Using this type of assessment, a decline in
spontaneous locomotor activity was suggested to arise
through pain and motor dysfunction in rat arthritis
models [9–11]. Recently, we developed a novel potent
JAK inhibitor, JTE-052, that was orally active in a rodent
model of RA [12] and as effective as other JAK inhibi-
tors such as tofacitinib. In the present study, we investi-
gated the effect of JAK inhibition on spontaneous
locomotor activity, and its relationships with joint in-
flammation and pain- and motor-related behaviors in a
rat AIA model using the novel JAK inhibitor JTE-052.
Methods
Animals
Lewis rats were obtained from Charles River Japan
(Atsugi, Japan) and maintained under specific pathogen-
free conditions at a room temperature of 23 ± 3 °C and
air humidity of 55 ± 15 % on a 12-h/12-h light/dark
cycle. All procedures related to the use of animals in this
study were reviewed and approved by the Institutional
Animal Care and Use Committee of Japan Tobacco Inc.
Compounds
JTE-052 was synthesized at the Central Pharmaceutical
Research Institute, Japan Tobacco Inc. (Osaka, Japan). In
an enzymatic assay, JTE-052 inhibited JAK1, JAK2,
JAK3, and Tyk2 with IC50 values of 2.8, 2.6, 13, and 58
nM, respectively [12]. Methotrexate hydrate (MTX) was
purchased from Sigma-Aldrich (St. Louis, MO). For in
vivo experiments, JTE-052 and MTX were suspended in
0.5 % (w/v) methylcellulose solution.
Induction of AIA
Arthritis was induced in the Lewis rats as previously
described [13]. Briefly, heat-killed Mycobacterium tuber-
culosis H37Ra (Difco Laboratories, Detroit, MI) was sus-
pended at 5 mg/mL in liquid paraffin, and the rats were
injected with 0.1 mL of the suspension into the base of
the tail on day 1 under anesthesia. The test drugs were
given orally once daily from day 15 to day 21. As an
index of paw swelling, the increase in hind paw volume
from baseline was measured by a water displacement
method using a plethysmometer for rats (Muromachi
Kikai Co. Ltd., Tokyo, Japan). The rats were euthanized
on day 22, and their hind paws were excised for X-ray
analysis or histological evaluation. Radiographs of the
right hindlimbs were obtained with a microfocal cone-
beam X-ray CT scanner (MCT-CB100MF; Hitachi Med-
ical Corporation, Tokyo, Japan). The severity of bone
destruction was scored for the tarsal bone and calcaneal
bone on a four-point scale from 0 to 3 (0: normal; 1:
mild; 2: moderate; 3: severe). For histological analysis,
the left hindlimbs were fixed in formalin, sectioned, and
stained with hematoxylin and eosin. The histology of the
tarsal joints was assessed using the following parameters
defined in a preliminary examination: inflammatory cell
infiltration; synovial cell hyperplasia; cartilage destruc-
tion; and bone destruction. The severity of each histo-
logical change was scored on a five-point scale from 0 to
4 (0: normal; 1: minimal solitary (and very small) lesions;
2: slight focal (and small) lesions; 3: moderate scattered
lesions; 4: severe extensive lesions).
Locomotor activity
The spontaneous locomotor activity of the rats was
assessed using a SUPERMEX apparatus (Muromachi
Kikai Co. Ltd., Tokyo, Japan) between 8:00 p.m. on day
21 and 8:00 a.m. on day 22 (dark cycle). Each rat was
placed in an individual automated activity box, compris-
ing a polycarbonate box (width × depth × height: 263 ×
426 × 202 mm) placed under external sensor units. The
rats were kept in the boxes for more than 1 h prior to
measurement of locomotor activity to exclude typical
exploratory behavior.
Measurement of hyperalgesia
Mechanical hyperalgesia was assessed on day 22 by
measuring the paw withdrawal threshold (PWT) as pre-
viously described [14] using a pressure analgesymeter
(Unicom, Chiba, Japan).
Inclined plane test and gait disturbance score
The motor function of the rats was evaluated by the in-
clined plane test and gait disturbance score on day 22.
The inclined plane test was performed as previously de-
scribed [15]. Briefly, the rats were placed on a 25° inclined
plane (model SN-453; Shinano Co. Ltd., Tokyo, Japan) in
the head-up position and the angle of the inclined plane
was increased at a rate of 2.5°/s from 30° to 60°. The max-
imum angle was determined at the moment when a limb
of the rat moved to maintain the body position. The test
was carried out three times and the mean value was calcu-
lated. The gait disturbance of the rats was scored for each
hind paw as follows: 0: no gait disturbance; 1: significant
disturbance in the hind paw; 2: paralysis of the hind paw.
The scores were then totaled.
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Measurement of serum IL-6
At 4 h after the initial administration of the test drugs on
day 15, blood samples were collected from the tail vein.
The serum IL-6 levels were quantified using an enzyme-
linked immunosorbent assay kit (Quantikine ® Rat IL-6
Immunoassay kit; R&D Systems Inc., Minneapolis, MN).
Statistical analysis
Data are expressed as means ± SD of the indicated num-
bers of samples. Statistical significance was assessed by
Dunnett’s test (for homoscedastic data) or the Steel test
(for heteroscedastic data) after homoscedasticity analysis
by Bartlett’s test. For radiographic or histological scores,
statistical significance was assessed by the Steel test. For
correlation analyses between spontaneous locomotor
activity and other parameters, statistical significance was
assessed by the Spearman test.
Results
JAK inhibition with JTE-052 suppresses inflammation and
joint destruction in AIA rats
To confirm the effects of JTE-052 on inflammatory arth-
ritis as a therapeutic treatment, we employed the rat
AIA model, as a widely used animal model for RA. AIA
was induced by injection of an M. tuberculosis suspen-
sion on day 1, and JTE-052 was orally administered once
daily for 7 days from the onset of arthritis (day 15).
MTX, an anchor drug for clinical treatment of RA, was
used as a reference drug. As shown in Fig. 1a, JTE-052
significantly attenuated the paw swelling in a dose-
dependent manner. Histological analysis of the hind
paws confirmed the presence of inflammatory cell infil-
tration, synovial cell hyperplasia, cartilage destruction,
and bone destruction in AIA rats on day 22, and re-
vealed that JTE-052 attenuated these symptoms in a
dose-dependent manner (Fig. 1b and c). Radiographic
assessment of the hind paws indicated bone destruction
in the tarsal and calcaneal bones of AIA rats on day 22,
which was significantly attenuated by JTE-052 (Fig. 1d
and e). Meanwhile, MTX at 0.3 mg/kg had no significant
effects on all of these symptoms in AIA rats, despite the
complete suppression of arthritis development when
administered preventively in AIA rats (data not shown).
JAK inhibition with JTE-052 improves spontaneous
locomotor activity in AIA rats
Next, we examined the effect of JTE-052 on spontaneous
locomotor activity. Induction of AIA significantly de-
creased the spontaneous locomotor activity from day 15
compared with non-AIA rats (16855 ± 5021 vs. 46897 ±
11215 counts/12 h), and the decrease was observed until
day 22 (19890 ± 2953 vs. 45508 ± 11525 counts/12 h).
JTE-052 dose-dependently ameliorated the spontaneous
locomotor activity, and complete remission was observed
at a dose of 10 mg/kg on day 22 when administered after
the onset of arthritis (Fig. 2). MTX had no significant
effect on the spontaneous locomotor activity when admin-
istered after the onset of arthritis. The ameliorating effect
of JTE-052 on the spontaneous locomotor activity was
correlated with that on paw swelling, as revealed by a cor-
relation analysis between paw volume and spontaneous
locomotor activity (r2 = 0.85, p < 0.01).
JAK inhibition with JTE-052 ameliorates the hyperalgesia
in AIA rats
To investigate the underlying mechanism by which JTE-
052 ameliorates the decrease in spontaneous locomotor
activity in AIA rats, the effect of JTE-052 on the mech-
anical hyperalgesia of AIA rats when administered after
the onset of arthritis was evaluated. Induction of AIA
significantly decreased the PWT of the hind paw
from day 14 compared with non-AIA rats (39.1 ± 6.7
vs. 111.0 ± 21.0 mmHg), and the decrease was ob-
served until day 22 (42.7 ± 15.8 vs. 114.6 ± 6.6 mmHg).
JTE-052 ameliorated the decrease in PWT in a dose-
dependent manner (Fig. 3), but the efficacy was not
complete. MTX had no significant effect on the
hyperalgesia. The ameliorating effect of JTE-052 on
the hyperalgesia was correlated with that on spontan-
eous locomotor activity, as revealed by a correlation
analysis between PWT and spontaneous locomotor
activity (r2 = 0.77, p < 0.01).
JAK inhibition with JTE-052 ameliorates the motor func-
tion in AIA rats
To further investigate the underlying mechanism by
which JTE-052 ameliorates the decrease in spontaneous
locomotor activity in AIA rats, the effect of JTE-052 on
the motor function of AIA rats when administered after
the onset of arthritis was investigated. The inclined
plane test was performed as an index of motor function.
The maximum angle for AIA rats decreased from day 15
compared with non-AIA rats (28.3 ± 2.6° vs. 49.6 ± 4.6°),
and the decrease was observed until day 22 (32.0 ± 4.7°
vs. 53.0 ± 4.8°). JTE-052 ameliorated the decrease in the
maximum angle on day 22 in a dose-dependent manner
(Fig. 4a). Next, the gait disturbance was investigated as a
separate index of motor function. The gait disturbance
score was increased in AIA rats from day 15 compared
with non-AIA rats (3.2 ± 0.8 vs. 0.0 ± 0.0), and continued
to increase until day 22 (3.6 ± 0.9 vs. 0.0 ± 0.0). JTE-052
decreased the gait disturbance score in a dose-
dependent manner (Fig. 4b). MTX had no significant
effect on the maximum angle in the inclined plane test
or the gait disturbance score (Fig. 4a and b). The ameli-
orating effects of JTE-052 on both the inclined plane test
and the gait disturbance score were correlated with that
on spontaneous locomotor activity, as revealed by
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Fig. 1 JAK inhibition with JTE-052 suppresses joint inflammation and joint destruction in rats with adjuvant-induced arthritis (AIA). Rat with clinical
signs of joint inflammation were orally administered vehicle, JTE-052 (0.1, 1, or 10 mg/kg), or methotrexate hydrate (MTX; 0.3 mg/kg) once daily
for 1 week from day 15. The volumes of the hind paws (a) were measured periodically. Hematoxylin and eosin-stained sections (b) and radiographs
(d) of the hindlimbs are shown. The histological (c) and radiographic (e) changes were scored. The results are expressed as means ± SD (n = 15).
*p < 0.05, **p < 0.01, versus vehicle by Dunnett’s test. #p < 0.05, ##p < 0.01, versus vehicle by the Steel test
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correlation analyses between the maximum angle or gait
disturbance score and spontaneous locomotor activity
(r2 = 0.61, p < 0.01 and r2 = 0.81, p < 0.01, respectively).
JTE-052 decreases serum IL-6 levels
To investigate the effect of JTE-052 on a fatigue-related
inflammatory mediator, the effect of JTE-052 on the
serum IL-6 levels of AIA rats when administered after
the onset of arthritis was analyzed. The serum IL-6
levels were increased in AIA rats compared with non-
treated rats, and JTE-052 suppressed the serum IL-6
levels at 4 h after the initial dose on day 15 (Fig. 5).
Discussion
In this study, we investigated the effect of the novel JAK
inhibitor JTE-052 on arthritis-induced behavioral
changes in an animal model of RA. Oral administration
of JTE-052 to AIA rats improved their spontaneous
locomotor activity, which was correlated with the ameli-
oration of articular inflammation, hyperalgesia, and
motor function. In addition, a decrease in serum IL-6
was observed after the first administration of JTE-052.
JAK inhibition by JTE-052 inhibited joint inflamma-
tion and joint destruction when administered after the
onset of arthritis. These findings are consistent with pre-
vious reports on two other JAK inhibitors, tofacitinib
and baricitinib [7, 8, 16]. Although JAK inhibition with
all three JAK inhibitors showed rapid and strong
Fig. 3 JAK inhibition with JTE-052 ameliorates hyperalgesia in rats
with adjuvant-induced arthritis (AIA). The mechanical hyperalgesia
of AIA rats was assessed by measuring the paw withdrawal threshold
(PWT) on day 22. The results are expressed as means ± SD (n = 5).
#p < 0.01, versus vehicle by the Steel test
Fig. 2 JAK inhibition with JTE-052 improves spontaneous locomotor
activity in rats with adjuvant-induced arthritis (AIA). The spontaneous
locomotor activity of AIA rats was assessed using a SUPERMEX apparatus
between 8:00 p.m. on day 21 and 8:00 a.m. on day 22. The results are
expressed as means ± SD (n = 5). *p < 0.05, **p< 0.01, versus vehicle by
Dunnett’s test
Fig. 4 JAK inhibition with JTE-052 ameliorates motor function in rats
with adjuvant-induced arthritis (AIA). An inclined plane test (a) was
performed and gait disturbance (b) was scored in rats on day 22.
The results are expressed as means ± SD (n = 5). *p < 0.05, **p < 0.01,
versus vehicle by Dunnett’s test. #p < 0.01, versus vehicle by the
Steel test
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suppressive effects on articular inflammation and joint
destruction when administered around the peak of arth-
ritis, the effects on the symptoms were not complete
(Fig. 1a) [7, 8]. Dosing with JTE-052 at 10 mg/kg from
the day before the induction of arthritis completely
inhibited AIA (data not shown) or CIA [12] in rats.
Therefore, it was thought that a dose of 10 mg/kg JTE-
052 would be sufficient to completely inhibit cytokine
signaling. A previous study reported that mediators
other than JAK-related cytokines, such as TNF-α, might
participate in the pathogenesis of rat AIA [17]. Serum
TNF-α was also reported to be increased after the onset
of arthritis in AIA rats [18]. These observations might
explain the incomplete efficacy of JAK inhibitors on AIA
in rats when administered after the onset of arthritis.
Under the same conditions, MTX failed to show inhibitory
effects at a dose that produced a complete inhibitory effect
when administered before the onset of arthritis (data not
shown). Currently, several pharmacological mechanisms of
action for MTX have been proposed, and reduction of
antigen-dependent T cell proliferation is largely responsible
for its anti-rheumatic effect [19]. D-penicillamine and
auranofin were also reported to inhibit T cell proliferation
[20, 21], but had no inhibitory effects on a rat AIA model
when administered after the onset of arthritis [22]. These
findings indicate that anti-arthritic drugs that inhibit T cell
proliferation do not ameliorate AIA when administered
after disease onset. However, JAK inhibitors were re-
ported to inhibit the activation of many types of
inflammatory cells, including B cells, neutrophils, and
macrophages, as well as that of T cells [12, 23, 24],
indicating that JAK inhibition by JAK inhibitors is
even efficacious when the inhibitors are administered
after the onset of arthritis.
In the present study, JAK inhibition by JTE-052 amelio-
rated the spontaneous locomotor activity in AIA rats, and
complete improvement was seen at a dose of 10 mg/kg. A
decline in spontaneous locomotor activity was observed
concurrently with reduced paw swelling in AIA rats, sug-
gesting that inhibition of articular inflammation by JAK
inhibition was a major cause of the improvement in spon-
taneous locomotor activity. Nevertheless, JTE-052 com-
pletely improved the spontaneous locomotor activity
despite its partial inhibition of articular inflammation. It
has been reported that tacrolimus improved spontaneous
locomotor activity without amelioration of paw swelling
when administered after the onset of arthritis in a rat CIA
model [10]. Thus, factors other than articular inflammation
may also participate in the improvement of locomotor
activity by JAK inhibition. Therefore, we investigated the
effects of JAK inhibition on factors that appeared to con-
tribute to the reduced locomotor activity, such as pain,
physical function, and fatigue, as important factors for
QOL in RA patients.
Pain is the most important problem in patients with
RA, and reduces their QOL [25, 26]. Administration of
analgesic agents was reported to improve the spontan-
eous locomotor activity in AIA rats [11], suggesting that
inhibition of hyperalgesia by JTE-052 is a likely cause of
the improvement in spontaneous locomotor activity.
However, the amelioration of hyperalgesia by JTE-052
was not complete, similar to the case for articular
inflammation. Although several pain-producing sub-
stances, such as bradykinin, nerve growth factor, prosta-
glandins, and ATP, were reported to be involved in
inflammatory pain [27], JAK provides little contribution
to the signaling of these substances. Therefore, it is sug-
gested that the inhibition of hyperalgesia by JAK
inhibition arises through inhibition of inflammation, and
that JAK inhibition does not ameliorate spontaneous
locomotor activity through direct inhibition of hyper-
algesia in AIA rats.
It has been reported that physical dysfunction can
arise through joint destruction resulting from cartilage
and bone destruction, and decrease the QOL of RA pa-
tients [28, 29]. Although there are few available reports,
it is easy to imagine the correlation between physical
function and spontaneous locomotor activity. Therefore,
in this study, we evaluated the effect of JAK inhibition
on motor function by the inclined plane test and gait
disturbance score to investigate the physical dysfunction.
Although JAK inhibition by JTE-052 ameliorated the
outcomes of both tests, the amelioration of motor
function was not complete and was comparable to the
Fig. 5 JAK inhibition with JTE-052 decreases the serum IL-6 levels in
rats with adjuvant-induced arthritis (AIA). The serum IL-6 levels were
assessed at 4 h after the first administration of JTE-052 on day 15.
The results are expressed as means ± SD (n = 15). *p < 0.05, **p < 0.01,
versus vehicle by Dunnett’s test
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amelioration of cartilage and bone destruction. In
addition, the amelioration of joint destruction by JTE-052
was comparable to the amelioration of joint inflammation,
suggesting that JAK inhibition by JTE-052 ameliorated
joint destruction through the inhibition of joint inflamma-
tion, rather than having a direct inhibitory effect on joint
destruction. These findings are consistent with a previous
report describing that JAK inhibition by tofacitinib ame-
liorated joint destruction by inhibiting the activation of in-
flammatory cells expressing RANKL and had no impact
on osteoclast differentiation and function [8]. Taken to-
gether, these findings indicate that inhibition of motor
function by JAK inhibition arises as a result of suppression
of joint destruction through the inhibition of joint inflam-
mation, and that JAK inhibition does not ameliorate spon-
taneous locomotor activity through direct inhibition of
physical function in AIA rats.
Fatigue is commonly reported in RA patients, with 41 %
experiencing clinically important levels of fatigue [30], and
can affect their QOL. In patients with RA, TNF-α and IL-
1 were thought to be the primary cytokines contributing
to the pathogenesis [31], and biologics targeting these
cytokines were reported to reduce fatigue [32, 33]. How-
ever, systemic upregulation of TNF-α was not as high and
upregulation of IL-1 was not observed in AIA rats [18]. In
contrast, other pro-inflammatory cytokines such as IL-6,
IL-17, transforming growth factor-β, and IL-18 were
clearly upregulated in AIA rats [18] and considered
to contribute to the pathogenesis of joint inflamma-
tion [34, 35]. Among them, IL-6 is another cytokine
that has been suggested to induce fatigue in RA
patients [36]. Furthermore, a tumor-induced decrease
in spontaneous locomotor activity was correlated with
the systemic levels of IL-6 in mice [37]. As JAK is
associated with the IL-6 receptor and has a role in
signaling [38], inhibition of JAK is thought to block
IL-6 signaling. In AIA rats, production of IL-6 was
observed in association with articular inflammation
and was reduced by JTE-052 (Fig. 5). Therefore, a
direct reduction of fatigue via inhibition of IL-6 pro-
duction as well as blockade of IL-6 signaling by JAK
inhibition may be involved in the improvement of
spontaneous locomotor activity in AIA rats. Moreover,
these findings suggest that the clinical improvement in
QOL of RA patients by JAK inhibitors such as tofacitinib
might include the improvement of fatigue by inhibition of
IL-6. Because the reduced spontaneous locomotor activity
may involve not only pain and physical function induced
by joint inflammation and joint destruction, but also
fatigue induced by systemic inflammation, which are com-
ponents of decreased QOL in humans, measurement of
spontaneous locomotor activity in animal models of RA
might be a useful index to assess the ameliorating actions
of agents on the QOL of RA patients.
Conclusions
In conclusion, we have demonstrated that JAK inhibition
by JTE-052 improved spontaneous locomotor activity in
AIA rats. The improvement was accompanied by ameli-
oration of pain and physical dysfunction as a conse-
quence of suppression of articular inflammation and
joint destruction. Moreover, although further studies are
needed, there was possible participation of IL-6 down-
regulation in the improvement of spontaneous loco-
motor activity by JAK inhibition.
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